Literature DB >> 1861679

Chemically unambiguous peptide immunogen: preparation, orientation and antigenicity of purified peptide conjugated to the multiple antigen peptide system.

Y A Lu1, P Clavijo, M Galantino, Z Y Shen, W Liu, J P Tam.   

Abstract

We described a novel and simple approach to prepare chemically unambiguous peptide immunogen using the multiple antigen peptide (MAP) approach. This approach requires the conjugation of two purified components: a chloroacetylated oligomeric lysine core matrix and a synthetic peptide containing cysteine at either the carboxyl or amino terminus. The resulting MAP is structurally unambiguous and contains a quantifiable amount of peptide antigens. Furthermore, this method also provides a flexible strategy to link a peptide antigen to the core matrix at the desirable orientation to mimic the native molecule. The carboxyl fragment 43-50 of human transforming growth factor alpha (TGF alpha) was used as a test model for this approach. Antipeptide antibodies did not recognize the "reverse immunogen" in which the peptide was attached to the MAP core matrix at a reverse orientation. To determine the specificity of the antibodies, we used two series of point-substituted TGF alpha analogs containing either alanine or the corresponding D-amino acid replacement to map the antigenic site. The alanine analogs were used to determine the contribution of the side chain while the D-amino acid analogs were used to determine the importance of backbone conformation. The antigen site was found to consist of four residues (Asp47-Leu48-Leu49-Ala50) at the distal end of the peptide-MAP conjugate. The results provide a clear explanation for the specificity of the antipeptide antibodies and their failure to recognize the "reverse immunogen" since the distal and the flexible end of the peptide-MAP construct constitutes the antigenic site. Furthermore, our results also suggests a strategy of placing the antigenic portion of a short-peptide at the distal end in the MAP approach to prepare immunogen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861679     DOI: 10.1016/0161-5890(91)90131-3

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  15 in total

1.  Immune responses in congenic mice to multiple antigen peptides based on defined epitopes from the malaria antigen Pf332.

Authors:  N Ahlborg; R Andersson; P Perlmann; K Berzins
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

2.  Immunogenicity of a contiguous T-B synthetic epitope of the A/PR/8/34 influenza virus.

Authors:  T D Brumeanu; S Casares; A Bot; S Bot; C A Bona
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Diepitopic construct of functionally and epitopically complementary peptides enhances immunogenicity, reactivity with glucosyltransferase, and protection from dental caries.

Authors:  M A Taubman; C J Holmberg; D J Smith
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers.

Authors:  S C Piller; G D Ewart; A Premkumar; G B Cox; P W Gage
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

5.  Characterization of PitA and PitB from Escherichia coli.

Authors:  R M Harris; D C Webb; S M Howitt; G B Cox
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

6.  How well can a T-cell epitope replace its parent carrier protein? A dose-response study.

Authors:  James S Cavenaugh; Hsu-Kun Wang; Cory Hansen; Richard S Smith; James N Herron
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

7.  Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.

Authors:  Y T Chen; E Stockert; Y Chen; P Garin-Chesa; W J Rettig; P van der Bruggen; T Boon; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

8.  Macromolecular assemblage in the design of a synthetic AIDS vaccine.

Authors:  J P Defoort; B Nardelli; W Huang; D D Ho; J P Tam
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

9.  Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine.

Authors:  Luciana M Silva-Flannery; Monica Cabrera-Mora; Jianlin Jiang; Alberto Moreno
Journal:  Microbes Infect       Date:  2008-10-26       Impact factor: 2.700

10.  The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels.

Authors:  G D Ewart; T Sutherland; P W Gage; G B Cox
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.